BUD vs PYXS
BUD (BUD) versus Pyxis Oncology Inc (PYXS) — a side-by-side from cached financials, not a winner call.
BUD (BUD) common stock.
Pyxis Oncology Inc (PYXS) is a biotechnology company listed on NASDAQ.
BUD does not have a complete income-statement cache yet.
Latest reported PYXS revenue for 2025-09-30 was $2.8M. Net income was -$22.0M. Revenue was up 0.0% from 2025-06-30 to 2025-09-30. PYXS currently screens at market cap $109.6M.
BUD currently screens at market cap $0. PYXS currently screens at market cap $109.6M.
Not investment advice. Open the BUD and PYXS stock pages for the full models.
Not investment advice.